Phenotype of CD4+CD25- and CD4+CD25bright T cells
. | . | . | . | . | Time after ASCT . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Healthy controls . | . | Before ASCT . | . | 1 month . | . | 6 months . | . | 1 year . | . | |||||
| Marker . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | |||||
| CTLA4, MFI | 9.1 ± 0.4 | 29.1 ± 1.0 | 11.0 ± 1.7 | 36.0 ± 11.5 | 29.2 ± 6.0 | 68.5 ± 11.6† | 14.4 ± 2.2 | 56.5 ± 9.6 | 10.0 ± 1.1 | 38.5 ± 9.9 | |||||
| GITR, % | 3.1 ± 0.6 | 27.0 ± 3.8 | 0.7 ± 0.2 | 9.9 ± 2.1* | 2.6 ± 1.1 | 21.1 ± 7.7 | 1.5 ± 0.5 | 14.9 ± 3.4 | 2.7 ± 0.9 | 19.2 ± 3.0 | |||||
| CCR4, % | 15.3 ± 1.6 | 62.1 ± 4.3 | 11.4 ± 3.8 | 33.1 ± 5.5* | 11.8 ± 1.1 | 65.4 ± 10.8† | 19.7 ± 2.7 | 64.8 ± 7.9† | 18.2 ± 2.0 | 69.8 ± 4.4† | |||||
| CD44, MFI | ND | ND | 5.9 ± 0.5 | 8.2 ± 0.5 | 9.6 ± 0.9 | 14.7 ± 1.9† | 7.6 ± 1.0 | 9.3 ± 1.2 | 9.4 ± 1.2 | 13.1 ± 1.8† | |||||
. | . | . | . | . | Time after ASCT . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Healthy controls . | . | Before ASCT . | . | 1 month . | . | 6 months . | . | 1 year . | . | |||||
| Marker . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | CD25- . | CD25bright . | |||||
| CTLA4, MFI | 9.1 ± 0.4 | 29.1 ± 1.0 | 11.0 ± 1.7 | 36.0 ± 11.5 | 29.2 ± 6.0 | 68.5 ± 11.6† | 14.4 ± 2.2 | 56.5 ± 9.6 | 10.0 ± 1.1 | 38.5 ± 9.9 | |||||
| GITR, % | 3.1 ± 0.6 | 27.0 ± 3.8 | 0.7 ± 0.2 | 9.9 ± 2.1* | 2.6 ± 1.1 | 21.1 ± 7.7 | 1.5 ± 0.5 | 14.9 ± 3.4 | 2.7 ± 0.9 | 19.2 ± 3.0 | |||||
| CCR4, % | 15.3 ± 1.6 | 62.1 ± 4.3 | 11.4 ± 3.8 | 33.1 ± 5.5* | 11.8 ± 1.1 | 65.4 ± 10.8† | 19.7 ± 2.7 | 64.8 ± 7.9† | 18.2 ± 2.0 | 69.8 ± 4.4† | |||||
| CD44, MFI | ND | ND | 5.9 ± 0.5 | 8.2 ± 0.5 | 9.6 ± 0.9 | 14.7 ± 1.9† | 7.6 ± 1.0 | 9.3 ± 1.2 | 9.4 ± 1.2 | 13.1 ± 1.8† | |||||
Phenotype of CD4+CD25- and CD4+CD25bright T cells of healthy controls and JIA patients before and after ASCT. The indicated markers were measured by FACS. Except when MFI (mean fluorescence intensity) is indicated, numbers are given as percentages (mean ± SEM of 8 patients).
ND indicates no data available.
Significant (P < .05) compared to healthy controls
Significant (P < .05) compared to the same population before ASCT